Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
UTHR [NASD]
United Therapeutics Corporation
Index- P/E39.40 EPS (ttm)3.39 Insider Own0.10% Shs Outstand47.51M Perf Week3.24%
Market Cap6.35B Forward P/E13.55 EPS next Y9.86 Insider Trans-64.49% Shs Float46.91M Perf Month4.34%
Income193.80M PEG3.05 EPS next Q2.13 Inst Own- Short Float9.81% Perf Quarter-0.09%
Sales1.23B P/S5.15 EPS this Y-42.60% Inst Trans1.25% Short Ratio5.87 Perf Half Y52.26%
Book/sh25.72 P/B5.19 EPS next Y39.59% ROA9.40% Target Price128.07 Perf Year53.94%
Cash/sh16.16 P/C8.27 EPS next 5Y12.90% ROE15.20% 52W Range84.63 - 137.84 Perf YTD18.11%
Dividend- P/FCF20.44 EPS past 5Y38.20% ROI11.80% 52W High-2.45% Beta1.32
Dividend %- Quick Ratio1.30 Sales past 5Y31.70% Gross Margin87.90% 52W Low58.88% ATR4.21
Employees706 Current Ratio1.40 Sales Q/Q9.20% Oper. Margin26.90% RSI (14)58.97 Volatility3.38% 3.31%
OptionableYes Debt/Eq0.24 EPS Q/Q-145.30% Profit Margin15.70% Rel Volume0.60 Prev Close133.56
ShortableYes LT Debt/Eq0.00 EarningsOct 28 BMO Payout0.00% Avg Volume783.71K Price134.46
Recom2.60 SMA202.69% SMA504.67% SMA20025.01% Volume361,013 Change0.67%
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Dec-31-13Reiterated Argus Buy $120 → $130
Dec-23-13Upgrade Ladenburg Thalmann Neutral → Buy $138
Dec-02-13Reiterated Argus Buy $85 → $110
Aug-05-13Reiterated Argus Buy $75 → $85
Jul-30-13Downgrade Standpoint Research Buy → Hold
Jun-20-13Upgrade Standpoint Research Hold → Buy
May-15-13Downgrade Standpoint Research Buy → Hold
Mar-25-13Reiterated Ladenburg Thalmann Buy $69 → $63
Feb-27-13Reiterated RBC Capital Mkts Sector Perform $45 → $50
Aug-03-12Downgrade Standpoint Research Buy → Hold
Apr-27-12Downgrade Canaccord Genuity Buy → Hold
Mar-26-12Initiated Canaccord Genuity Buy $56
Mar-12-12Initiated Standpoint Research Buy $65
Dec-19-14 05:20PM  United Therapeutics Lung Drug Keeps Going And Going at Investor's Business Daily
Dec-17-14 06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ EDGAR Online
06:00AM  United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change PR Newswire
Dec-11-14 11:48AM  Can United Therapeutics find a remedy for recent resistance? at Investor's Business Daily
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
Nov-26-14 05:40PM  Stock Market Today: Top Biotech Is Near Buy Point at Investor's Business Daily
Nov-13-14 06:44AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:00AM  Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors PR Newswire
Nov-03-14 08:45AM  United Therapeutics downgraded by Argus Briefing.com
Nov-01-14 01:04PM  UNITED THERAPEUTICS CORP Financials EDGAR Online Financials
Oct-30-14 08:08PM  10-Q for United Therapeutics Corp. Company Spotlight
07:59PM  Apple CEO publicly acknowledges that he's gay AP
Oct-29-14 11:50AM  United Therapeutics Falls on Q3 Loss, Revenues Miss Zacks
Oct-28-14 07:07AM  Q3 2014 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:27AM  United Therapeutics reports 3Q loss AP
06:05AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Third Quarter 2014 Financial Results PR Newswire
Oct-22-14 05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
Oct-21-14 06:00AM  United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014 PR Newswire
Oct-14-14 05:05PM  Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Zacks
10:27AM  J&J Beats Q3 Earnings on Strong Drug Sales, Ups View Zacks
Sep-26-14 03:07PM  Biotech's future: The Government is key Yahoo Finance
Sep-25-14 12:34PM  Artificial intelligence doppelgangers and life in outer space closer than you think Yahoo Finance
08:38AM  Highest-paid female CEO used to be a man Yahoo Finance
Sep-24-14 09:36AM  Can the Uptrend Continue for United Therapeutics (UTHR)? Zacks
Sep-23-14 05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
08:10AM  Moving Average Crossover Alert: United Therapeutics (UTHR) Zacks
Sep-22-14 05:11PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
Sep-17-14 07:30AM  Axsome Therapeutics Announces Appointments to Its Board of Directors GlobeNewswire
Sep-16-14 03:00AM  Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market GlobeNewswire
Sep-15-14 05:32PM  Today's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
11:19AM  Hedge fund offers $1 million to cure...aging? at CNBC
Sep-10-14 04:20PM  Spectrum Pharmaceuticals to Advance Neutropenia Drug Zacks
Sep-09-14 03:50PM  Pluristem & United Therapeutics Progress with Phase I Study Zacks
Sep-03-14 04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
Sep-02-14 05:25PM  United Therapeutics Soars on Remodulin Patent Case Win Zacks
07:58AM  United Therapeutics (UTHR) Shares March Higher, Can It Continue? Zacks
Aug-29-14 04:21PM  United Therapeutics Legal Victory Sends Stock Flying at Investor's Business Daily +28.51%
02:21PM  United Therapeutics Up 27% as Patent Win 'Close to a Best Case Scenario' at Barrons.com
02:02PM  United Therapeutics rises on drug-patent ruling AP
12:49PM  District Court Decision Received In Remodulin Patent Case PR Newswire
Aug-26-14 07:50AM  Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% Zacks
Aug-25-14 11:05AM  Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals StockTwits
Aug-22-14 04:40PM  OncoGenex's Custirsen Passes First Interim Futility Analysis Zacks
08:25AM  Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Zacks
Aug-21-14 08:56AM  Gilead (GILD) Hits 52-Week High Thanks to Sovaldi Zacks
Aug-20-14 05:21PM  Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX Zacks
08:40AM  Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher Zacks
06:51AM  Can United Therapeutics (UTHR) Keep the Earnings Streak Alive This Quarter? Zacks
Aug-14-14 02:30PM  Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Zacks
Jul-31-14 12:20PM  United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat Zacks
Jul-30-14 10:56AM  Perilous Reversal Watch: United Therapeutics (UTHR) at TheStreet -5.01%
07:08AM  United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Zacks
Jul-29-14 07:07AM  Q2 2014 United Therapeutics Earnings Release - Before Market Open CCBN +8.10%
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Second Quarter 2014 Financial Results PR Newswire
Jul-22-14 06:00AM  United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014 PR Newswire
Jul-10-14 03:43PM  Supernus Up on Non-Dilutive Royalty Deal Zacks
Jul-09-14 05:00PM  Pluristem Initiates Trial in South Korea Zacks
Jul-08-14 07:30AM  Supernus to Receive $30 Million in Non-Dilutive Royalty Deal GlobeNewswire
05:47AM  United Therapeutics draws bulls optionMONSTER
Jun-27-14 09:14AM  Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals at Motley Fool
06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc EDGAR Online
06:00AM  United Therapeutics Announces Additional $500 Million Share Repurchase Program PR Newswire
Jun-19-14 01:18PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty Business Wire
Jun-16-14 09:49AM  United Therapeutics (UTHR) Marked As A Dead Cat Bounce Stock at TheStreet
07:26AM  Weakness Seen in United Therapeutics (UTHR): Stock Tumbles 8.0% Zacks
Jun-13-14 04:46PM  Can Pig Lungs Keep Growth Flying for United Therapeutics Shareholders? at Motley Fool -7.97%
Jun-09-14 02:34PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty PR Newswire
May-21-14 05:34PM  [video] Momentum trades alive: ARCB, UTHR at CNBC
May-20-14 05:00PM  Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM) GlobeNewswire
11:19AM  Why I'm Long Supernus, A Small Specialty Pharma Company at Seeking Alpha
May-13-14 11:12AM  3 picks for bent but not broken biotech Breakout
May-11-14 05:45AM  Industry Ranks May 2014 at Seeking Alpha
May-08-14 12:16PM  Insider Trading Alert - K, EQR And UTHR Traded By Insiders at TheStreet
May-06-14 06:07AM  Pig organ transplants to humans move a step closer at Financial Times
06:00AM  Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc., a Subsidiary of United Therapeutics Corporation, to Develop Humanized Pig Organs to Revolutionize Transplantation Field PR Newswire
06:00AM  Genome scientist Craig Venter in deal to make humanized pig organs Reuters
May-05-14 06:32PM  3 Biotech Stocks Making Big Moves Last Week at Motley Fool
May-01-14 12:10PM  United Therapeutics Gains on Q1 Earnings Zacks
Apr-29-14 06:00PM  United Therapeutics Management Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha +6.13%
07:07AM  Q1 2014 United Therapeutics Earnings Release - Before Market Open CCBN
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports First Quarter 2014 Financial Results PR Newswire
Apr-22-14 06:00AM  United Therapeutics Corporation To Announce First Quarter 2014 Financial Results Before Market Open On Tuesday, April 29, 2014 PR Newswire
Apr-01-14 04:03AM  United Therapeutics: 7 Different Insiders Have Sold Shares This Month at Seeking Alpha
Mar-26-14 05:33PM  [video] The false temptation of growth at CNBC
09:13AM  Todays Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam at Motley Fool
06:00AM  Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin PR Newswire
Mar-18-14 04:31PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Mar-16-14 05:16PM  Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook at Seeking Alpha
Mar-11-14 01:56PM  United Therapeutics retreats after FDA denies petition on Remodulin label at theflyonthewall.com
12:52PM  United Therapeutics: A Profitable Biotech With A Potentially Undervalued Pipeline at Seeking Alpha
12:24PM  United Therapeutics lower after FDA denies Remodulin citizen petition at theflyonthewall.com
Feb-27-14 08:10AM  United Therapeutics Slips on Q4 Earnings Report Zacks
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAUSEY CHRISTOPHERDirectorDec 19Option Exercise41.141,50061,7102,233Dec 19 05:38 PM
CAUSEY CHRISTOPHERDirectorDec 19Sale131.471,500197,205733Dec 19 05:38 PM
ROTHBLATT MARTINE ACEODec 18Option Exercise32.379,662312,7855,687Dec 19 05:21 PM
MAHON PAUL AEVP & General CounselDec 18Option Exercise32.0810,750344,90340,832Dec 19 05:35 PM
Ferrari John MaximCFODec 18Option Exercise51.3710,000513,70010,407Dec 19 05:42 PM
ROTHBLATT MARTINE ACEODec 18Sale129.069,6621,246,931140Dec 19 05:21 PM
MAHON PAUL AEVP & General CounselDec 18Sale130.0310,7501,397,82834,832Dec 19 05:35 PM
Ferrari John MaximCFODec 18Sale131.1110,0001,311,100407Dec 19 05:42 PM
ROTHBLATT MARTINE ACEODec 17Option Exercise63.222,211139,7792,351Dec 18 04:01 PM
ROTHBLATT MARTINE ACEODec 17Sale126.042,211278,668140Dec 18 04:01 PM
ROTHBLATT MARTINE ACEODec 15Option Exercise52.652,592136,4692,732Dec 16 05:52 PM
ROTHBLATT MARTINE ACEODec 15Sale129.752,592336,314140Dec 16 05:52 PM
ROTHBLATT MARTINE ACEODec 11Option Exercise32.379,662312,7855,687Dec 15 07:26 AM
ROTHBLATT MARTINE ACEODec 11Sale130.989,6621,265,540140Dec 15 07:26 AM
ROTHBLATT MARTINE ACEODec 10Option Exercise63.222,211139,7792,351Dec 11 08:15 AM
ROTHBLATT MARTINE ACEODec 10Sale132.772,211293,544140Dec 11 08:15 AM
JEFFS ROGERPresident & COODec 09Option Exercise50.0910,000500,90011,234Dec 09 07:21 PM
JEFFS ROGERPresident & COODec 09Sale134.8010,0001,348,0001,234Dec 09 07:21 PM
ROTHBLATT MARTINE ACEODec 08Option Exercise52.652,592136,4692,732Dec 08 08:08 PM
ROTHBLATT MARTINE ACEODec 08Sale132.342,592343,013140Dec 08 08:08 PM
ROTHBLATT MARTINE ACEODec 04Option Exercise32.379,662312,7855,687Dec 04 07:30 PM
CAUSEY CHRISTOPHERDirectorDec 04Option Exercise41.141,50061,7102,233Dec 04 07:35 PM
DWEK RAYMONDDirectorDec 04Option Exercise31.173,00093,5103,000Dec 04 07:39 PM
MAHON PAUL AEVP & General CounselDec 04Option Exercise32.0511,000352,59040,832Dec 04 07:47 PM
PATUSKY CHRISTOPHERDirectorDec 04Option Exercise41.145,000205,7005,000Dec 04 07:50 PM
Ferrari John MaximCFODec 04Option Exercise51.3710,000513,70010,407Dec 04 07:53 PM
DWEK RAYMONDDirectorDec 04Sale131.583,000394,7510Dec 04 07:39 PM
MAHON PAUL AEVP & General CounselDec 04Sale129.9211,0001,429,12334,832Dec 04 07:47 PM
CAUSEY CHRISTOPHERDirectorDec 04Sale131.471,500197,206733Dec 04 07:35 PM
ROTHBLATT MARTINE ACEODec 04Sale131.019,6621,265,778140Dec 04 07:30 PM
PATUSKY CHRISTOPHERDirectorDec 04Sale129.055,000645,2500Dec 04 07:50 PM
Ferrari John MaximCFODec 04Sale129.0510,0001,290,500407Dec 04 07:53 PM
ROTHBLATT MARTINE ACEODec 03Option Exercise63.222,211139,7792,351Dec 04 07:30 PM
ROTHBLATT MARTINE ACEODec 03Sale132.682,211293,354140Dec 04 07:30 PM
JEFFS ROGERPresident & COODec 02Option Exercise50.0910,000500,90011,234Dec 03 05:30 PM
JEFFS ROGERPresident & COODec 02Sale133.6310,0001,336,3001,234Dec 03 05:30 PM
ROTHBLATT MARTINE ACEODec 01Option Exercise52.652,592136,4692,732Dec 02 09:21 AM
ROTHBLATT MARTINE ACEODec 01Sale132.922,592344,518140Dec 02 09:21 AM
ROTHBLATT MARTINE ACEONov 28Option Exercise32.379,662312,7855,687Nov 28 09:45 PM
ROTHBLATT MARTINE ACEONov 28Sale133.289,6621,287,786140Nov 28 09:45 PM
ROTHBLATT MARTINE ACEONov 26Option Exercise63.222,211139,7792,351Nov 28 09:45 PM
ROTHBLATT MARTINE ACEONov 26Sale130.522,211288,581140Nov 28 09:45 PM
JEFFS ROGERPresident & COONov 25Option Exercise50.0910,000500,90011,234Nov 25 06:55 PM
JEFFS ROGERPresident & COONov 25Sale131.3010,0001,313,0001,234Nov 25 06:55 PM
ROTHBLATT MARTINE ACEONov 24Option Exercise52.652,592136,4692,732Nov 24 04:59 PM
ROTHBLATT MARTINE ACEONov 24Sale130.722,592338,831140Nov 24 04:59 PM
JEFFS ROGERPresident & COONov 21Option Exercise30.7510,000307,50011,234Nov 21 05:13 PM
JEFFS ROGERPresident & COONov 21Sale130.1510,0001,301,4621,234Nov 21 05:13 PM
CAUSEY CHRISTOPHERDirectorNov 20Option Exercise41.141,50061,7102,233Nov 20 04:10 PM
ROTHBLATT MARTINE ACEONov 20Option Exercise32.379,662312,7855,687Nov 21 04:53 PM
MAHON PAUL AEVP & General CounselNov 20Option Exercise32.0511,000352,59040,832Nov 21 05:07 PM
Ferrari John MaximCFONov 20Option Exercise51.3710,000513,70010,407Nov 21 05:19 PM
CAUSEY CHRISTOPHERDirectorNov 20Sale127.201,500190,800733Nov 20 04:10 PM
ROTHBLATT MARTINE ACEONov 20Sale128.869,6621,245,016140Nov 21 04:53 PM
MAHON PAUL AEVP & General CounselNov 20Sale129.0211,0001,419,23934,832Nov 21 05:07 PM
Ferrari John MaximCFONov 20Sale129.2210,0001,292,200407Nov 21 05:19 PM
ROTHBLATT MARTINE ACEONov 19Option Exercise63.222,211139,7792,351Nov 20 04:09 PM
ROTHBLATT MARTINE ACEONov 19Sale128.692,211284,532140Nov 20 04:09 PM
JEFFS ROGERPresident & COONov 18Option Exercise50.0910,000500,90011,234Nov 18 08:20 PM
JEFFS ROGERPresident & COONov 18Sale128.2110,0001,282,1001,234Nov 18 08:20 PM
ROTHBLATT MARTINE ACEONov 17Option Exercise52.652,592136,4692,732Nov 18 08:04 PM
ROTHBLATT MARTINE ACEONov 17Sale125.652,592325,689140Nov 18 08:04 PM
ROTHBLATT MARTINE ACEONov 13Option Exercise32.379,662312,7855,687Nov 17 06:57 AM
ROTHBLATT MARTINE ACEONov 13Sale124.799,6621,205,706140Nov 17 06:57 AM
ROTHBLATT MARTINE ACEONov 12Option Exercise63.222,211139,7792,351Nov 13 06:09 PM
ROTHBLATT MARTINE ACEONov 12Sale122.882,211271,694140Nov 13 06:09 PM
ROTHBLATT MARTINE ACEONov 10Option Exercise52.652,592136,4692,732Nov 10 07:57 PM
ROTHBLATT MARTINE ACEONov 10Sale125.142,592324,363140Nov 10 07:57 PM
PATUSKY CHRISTOPHERDirectorNov 07Option Exercise30.755,000153,7505,000Nov 07 08:37 PM
JEFFS ROGERPresident & COONov 07Option Exercise30.7510,000307,50011,234Nov 07 08:50 PM
Ferrari John MaximCFONov 07Option Exercise51.2710,000512,70010,407Nov 07 08:55 PM
PATUSKY CHRISTOPHERDirectorNov 07Sale124.495,000622,4400Nov 07 08:37 PM
JEFFS ROGERPresident & COONov 07Sale124.4610,0001,244,6221,234Nov 07 08:50 PM
Ferrari John MaximCFONov 07Sale125.3310,0001,253,300407Nov 07 08:55 PM
MAHON PAUL AEVP & General CounselNov 06Option Exercise30.755,000153,75039,832Nov 06 04:49 PM
MAHON PAUL AEVP & General CounselNov 06Option Exercise33.146,000198,84045,832Nov 07 09:04 PM
DWEK RAYMONDDirectorNov 06Option Exercise31.173,00093,5103,000Nov 06 04:58 PM
CAUSEY CHRISTOPHERDirectorNov 06Option Exercise41.141,50061,7102,233Nov 06 04:57 PM
ROTHBLATT MARTINE ACEONov 06Option Exercise30.755,547170,5705,687Nov 06 05:01 PM
MAHON PAUL AEVP & General CounselNov 06Sale125.025,000625,11934,832Nov 06 04:49 PM
MAHON PAUL AEVP & General CounselNov 06Sale125.336,000751,98034,832Nov 07 09:04 PM
DWEK RAYMONDDirectorNov 06Sale122.893,000368,6700Nov 06 04:58 PM
CAUSEY CHRISTOPHERDirectorNov 06Sale122.891,500184,335733Nov 06 04:57 PM
ROTHBLATT MARTINE ACEONov 06Sale125.035,547693,527140Nov 06 05:01 PM
ROTHBLATT MARTINE ACEONov 05Option Exercise63.222,211139,7792,351Nov 05 06:35 PM
ROTHBLATT MARTINE ACEONov 05Sale124.312,211274,850140Nov 05 06:35 PM
ROTHBLATT MARTINE ACEONov 03Option Exercise52.652,592136,4692,732Nov 03 09:04 PM
ROTHBLATT MARTINE ACEONov 03Sale127.492,592330,451140Nov 03 09:04 PM
ROTHBLATT MARTINE ACEOOct 30Option Exercise32.379,662312,7855,687Oct 31 04:11 PM
ROTHBLATT MARTINE ACEOOct 30Sale130.429,6621,260,116140Oct 31 04:11 PM
ROTHBLATT MARTINE ACEOOct 29Option Exercise63.222,211139,7792,351Oct 30 04:30 PM
ROTHBLATT MARTINE ACEOOct 29Sale131.102,211289,858140Oct 30 04:30 PM
ROTHBLATT MARTINE ACEOOct 27Option Exercise52.652,592136,4692,732Oct 29 04:48 PM
ROTHBLATT MARTINE ACEOOct 27Sale132.162,592342,549140Oct 29 04:48 PM
ROTHBLATT MARTINE ACEOOct 23Option Exercise32.379,662312,7855,687Oct 23 09:26 PM
MAHON PAUL AEVP & General CounselOct 23Option Exercise30.755,000153,75039,832Oct 23 08:49 PM
ROTHBLATT MARTINE ACEOOct 23Sale130.209,6621,258,037140Oct 23 09:26 PM
MAHON PAUL AEVP & General CounselOct 23Sale130.235,000651,16434,832Oct 23 08:49 PM
ROTHBLATT MARTINE ACEOOct 22Option Exercise63.222,211139,7792,351Oct 23 09:26 PM
ROTHBLATT MARTINE ACEOOct 22Sale128.932,211285,073140Oct 23 09:26 PM